Due to the government shutdown, the Doubletree has extended their hotel cutoff for reservations until October 26th
There is no registration fee to attend but space is limited and early registration is encouraged.
Scope of the 14th ICMAOIThe ICMAOI is the only forum that is solely focused on presentation of basic, epidemiologic, and clinical aspects of research on malignancies in HIV-infected and other immunosuppressed individuals. Our objective is to enable information exchange between laboratory and clinically based investigators to decrease the interval between basic discovery and clinical application. This conference will address basic and clinical research on viral oncology, immunology, genetics, epidemiology, pathogenesis, drug discovery, early diagnosis, and clinical investigation of malignant diseases in AIDS and other immunodeficiency states including organ transplantation. We anticipate an emphasis on human papillomavirus (HPV), Epstein-Barr virus (EBV), and Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) and their related malignancies including lymphomas, ano-genital carcinomas, Kaposi's sarcoma, and Hodgkin's disease. Translational objectives such as basic target identification and validation, and preventive or therapeutic interventions are of particular interest. Other topics include interactions between viruses, somatic cell genetic changes, inherited and environmental risk factors, molecular genetics and biomarkers of disease, experimental models, novel clinical and therapeutic observations, epidemiology of etiologic agents or disease and clinical outcomes.
Who should attend the 14th ICMAOI?The format will include invited plenaries as well as oral and poster presentations of submitted abstracts. This conference is organized to provide informational and networking resources for all clinical and laboratory investigators; postdocs; students; physicians; health care workers and others involved, interested, or participating in malignancy research in HIV/AIDS and other immunodeficiencies and in tumor virology. Participants from resource-limited countries with endemic virus-associated malignancies are encouraged to submit abstracts.
NIH Visitor InformationSecurity screening is required for access to the National Institutes of Health (NIH) campus. Please have valid photo identification available to present to security personnel and inform them that you are attending a conference at the Lister Hill Center Auditorium . Please arrive early to allow ample time for the security procedures, which can take as long as 30 minutes. Be sure to bring proper identification, such as your driver’s license or a passport. All laptops and bags will be inspected. If you are driving, your vehicle will also be inspected. For more information about visiting NIH and NIH off-campus buildings, visit http://www.nih.gov/about/visitorsecurity.htm.
MetroThe preferred mode of transportation to NIH is the Metro because of the limited parking on the NIH campus. If you travel by Metro, exit the Metro at the Medical Center Station on the Red Line. When you exit the Metro Station, the Natcher Conference Center will be to the south. For more information on public transportation please visit http://www.wmata.com/.
If you plan to drive to the conference, there is limited public parking in the lot adjacent to the Natcher Conference Center (Building 45). There is also parking in Lot 41 to the right of the Lister Hill Center and across the street from the Natcher Conference Center. Parking costs $2 per hour for the first 3 hours and $12 for all-day parking.
Reasonable AccommodationsIf you are a person with a disability and require any assistive device, service, or other reasonable accommodations to participate in the event, please contact Susan Kerin at (301) 468-6004 ext. 459, or email@example.com.